Difference between revisions of "Part:BBa K4165196"

Line 7: Line 7:
 
===Usage and Biology===
 
===Usage and Biology===
 
Type of Amyloid-beta binding peptide start from amino acid 35 to 42, this peptide characterized by its solubility which is 149 ± 33 μm.  
 
Type of Amyloid-beta binding peptide start from amino acid 35 to 42, this peptide characterized by its solubility which is 149 ± 33 μm.  
 +
 +
===<span class='h3bb'>Sequence and Features</span>===
 +
<partinfo>BBa_K4165196 SequenceAndFeatures</partinfo>
  
 
===Features and codon optimize===
 
===Features and codon optimize===
Line 27: Line 30:
 
                                   Figure 1.: Amyloid-beta (35-42) top model visualized by Pymol.
 
                                   Figure 1.: Amyloid-beta (35-42) top model visualized by Pymol.
 
    
 
    
<!-- -->
 
<span class='h3bb'>Sequence and Features</span>
 
<partinfo>BBa_K4165196 SequenceAndFeatures</partinfo>
 
 
  
 
<!-- Uncomment this to enable Functional Parameter display  
 
<!-- Uncomment this to enable Functional Parameter display  

Revision as of 17:58, 10 October 2022


Amyloid beta peptide 16 (Aβ 35-42)

This part encodes a part of the Amyloid 𝛽 fragment (35-42) which has the ability to bind to A𝛽 plaques inside the brain.

Usage and Biology

Type of Amyloid-beta binding peptide start from amino acid 35 to 42, this peptide characterized by its solubility which is 149 ± 33 μm.

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]

Features and codon optimize

This sequence is optimized for E. coli bacteria

Source

Homo sapiens Amyloid-beta precursor protein - UniProt (P05067)

References

1-Zhao, Y., Cai, J., Liu, Z., Li, Y., Zheng, C., Zheng, Y., ... & Liu, Y. (2018). Nanocomposites inhibit the formation, mitigate the neurotoxicity, and facilitate the removal of β-amyloid aggregates in Alzheimer’s disease mice. Nano letters, 19(2), 674-683.

Dry lab

Modeling

Due to the nonavailability of a model to this peptide we modeled it in our used modeling software's and after the Running of the quality assessment, the models have been scored to get the top model.

                                 Figure 1.: Amyloid-beta (35-42) top model visualized by Pymol.